Citius Oncology, Inc. (CTOR)

NASDAQ: CTOR · Real-Time Price · USD

1.640

-0.150 (-8.38%)

Aug 14, 2025, 11:37 AM - Market open

Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Net Income	-26.58	-21.15	-12.7	-10.87
Stock-Based Compensation	7.69	7.5	1.97	-
Other Operating Activities	0.94	0.58	0.58	1.15
Change in Inventory	-11.07	-2.13	-	-
Change in Accounts Payable	8.67	2.42	1.2	0.18
Change in Other Net Operating Assets	20.48	12.91	8.96	9.53
Operating Cash Flow	0.13	0.13	-	-
Sale (Purchase) of Intangibles	-5	-5	-	-
Investing Cash Flow	-5	-5	-	-
Long-Term Debt Issued	-	3.8	-	-
Net Debt Issued (Repaid)	3.8	3.8	-	-
Other Financing Activities	1.07	1.07	-	-
Financing Cash Flow	4.87	4.87	-	-
Net Cash Flow	0	0	-	-
Levered Free Cash Flow	-0.04	-1.94	4.55	-
Unlevered Free Cash Flow	0.06	-1.94	4.55	-
Change in Working Capital	18.08	13.2	10.16	9.71

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q